Carcinoid tumors

New England Journal of Medicine

Volumn 340, Issue 11, 1999, Pages 858-868

  Kulke, Matthew H ^a,b   Mayer, Robert J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOSTATIN DERIVATIVE;

APPENDIX TUMOR; CARCINOID; COLON TUMOR; DISEASE CLASSIFICATION; HEART DISEASE; HUMAN; INCIDENCE; LIVER METASTASIS; LUNG TUMOR; PRIORITY JOURNAL; REVIEW; SMALL INTESTINE TUMOR; STOMACH TUMOR;

CARCINOID HEART DISEASE; CARCINOID TUMOR; GASTROINTESTINAL NEOPLASMS; HUMANS; INCIDENCE; LIVER NEOPLASMS; LUNG NEOPLASMS; MALIGNANT CARCINOID SYNDROME; SOMATOSTATIN; UNITED STATES;

EID: 0033580464     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199903183401107     Document Type: Review

References (135)

1. Lubarsch O. Ueber den primären Krebs des Ileum, nebst Bemerkungen über das gleichzeitige Vorkommen von Krebs und Tuberkolose. Virchows Arch 1888;111:280-317.
2. Oberndorfer S. Karzinoide Tumoren des Dünndarms. Frankf Z Pathol 1907;1:425-9.
3. Limper AH, Carpenter PC, Scheithauer B, Staats BA. The Cushing syndrome induced by bronchial carcinoid tumors. Ann Intern Med 1992;117: 209-14.
4. Pernow B, Waldenström J. Determination of 5-hydroxytryptamine, 5-hydroxyindole acetic acid, and histamine in thirty-three cases of carcinoid tumor (argentaffinoma). Am J Med 1957;23:16-25.
5. Feldman J. Increased dopamine production in patients with carcinoid tumors. Metabolism 1985;34:255-60.
6. Skrabanek P, Cannon D, Kirrane J, Powell D. Substance P secretion by carcinoid tumours. Ir J Med Sci 1978;147:47-9.
7. Feldman JM, O'Dorisio TM. Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors. Am J Med 1986;81:Suppl 6B:41-8.
8. Sandler M, Karim SM, Williams ED. Prostaglandins in amine-peptide-secreting tumours. Lancet 1968;2:1053-4.
9. Lucas KJ, Feldman JM. Flushing in the carcinoid syndrome and plasma kallikrein. Cancer 1986;58:2290-3.
10. Thorson Å, Biörck G, Björkman G, Waldenström J. Malignant carcinoid of the small intestine with metastases to the liver, valvular disease of the right side of the heart (pulmonary stenosis and tricuspid regurgitation without septal defects), peripheral vasomotor symptoms, bronchoconstriction, and an unusual type of cyanosis: a clinical and pathological syndrome. Am Heart J 1954;47:795-817.
11. Williams ED, Sandler M. The classification of carcinoid tumours. Lancet 1963;1:238-9.
12. Capella C, Heitz PU, Hofler H, Solcia E, Kloppel G. Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch 1995;425:547-60.
13. Soga J, Tazawa K. Pathologic analysis of carcinoids: histologic reevaluation of 62 cases. Cancer 1971;28:990-8.
14. Godwin J. Carcinoid tumors: an analysis of 2837 cases. Cancer 1975; 36:560-9.
15. Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer 1997;79:813-29.
16. Berge T, Linell F. Carcinoid tumours: frequency in a defined population during a 12-year period. Acta Pathol Microbiol Scand [A] 1976;84: 322-30.
17. Harpole DH Jr, Feldman JM, Buchanan S, Young WG, Wolfe WG. Bronchial carcinoid tumors: a retrospective analysis of 126 patients. Ann Thorac Surg 1992;54:50-5.
18. Vadasz P, Palffy G, Egervary M, Schaff Z. Diagnosis and treatment of bronchial carcinoid tumors: clinical and pathological review of 120 operated patients. Eur J Cardiothorac Surg 1993;7:8-11.
19. Gould VE, Linnoila RI, Memoli VA, Warren WH. Neuroendocrine components of the bronchopulmonary tract: hyperplasias, dysplasias, and neoplasms. Lab Invest 1983;49:519-37.
20. Paladugu RR, Benfield JR, Pak HY, Ross RK, Teplitz RL. Bronchopulmonary Kulchitzky cell carcinomas: a new classification scheme for typical and atypical carcinoids. Cancer 1985;55:1303-11.
21. Warren WH, Gould VE, Faber LP, Kittle CF, Memoli VA. Neuroendocrine neoplasms of the bronchopulmonary tract: a classification of the spectrum of carcinoid to small cell carcinoma and intervening variants. J Thorac Cardiovasc Surg 1985;89:819-25.
22. Torre M, Barberis M, Barbieri B, Bonacina E, Belloni P. Typical and atypical bronchial carcinoids. Respir Med 1989;83:305-8.
23. Okike N, Bernatz PE, Woolner LB. Carcinoid tumors of the lung. Ann Thorac Surg 1976;22:270-7.
24. Carroll DG, Delahunt JW, Teague CA, et al. Resolution of acromegaly after removal of a bronchial carcinoid shown to secrete growth hormone releasing factor. Aust N Z J Med 1987;17:63-7.
25. Rea F, Binda R, Spreafico G, et al. Bronchial carcinoids: a review of 60 patients. Ann Thorac Surg 1989;47:412-4.
26. McCaughan BC, Martini N, Bains MS. Bronchial carcinoids: review of 124 cases. J Thorac Cardiovasc Surg 1985;89:8-17.
27. Chughtai TS, Morin JE, Sheiner NM, Wilson JA, Mulder DS. Bronchial carcinoid - twenty years' experience defines a selective surgical approach. Surgery 1997;122:801-8.
28. Schreurs AJ, Westermann CJ, Bosch JM, Vanderschueren RG, Riviere A, Knaepen PJ. A twenty-five-year follow-up of ninety-three resected typical carcinoid tumors of the lung. J Thorac Cardiovasc Surg 1992;104: 1470-5.
29. Smolle-Juttner FM, Popper H, Klemen H, et al. Clinical features and therapy of "typical" and "atypical" bronchial carcinoid tumors (grade 1 and grade 2 neuroendocrine carcinoma). Eur J Cardiothorac Surg 1993;7: 121-5.
30. Marty-Ane CH, Costes V, Pujol JL, Alauzen M, Baldet P, Mary H. Carcinoid tumors of the lung: do atypical features require aggressive management? Ann Thorac Surg 1995;59:78-83.
31. Dusmet ME, McKneally MF. Pulmonary and thymic carcinoid tumors. World J Surg 1996;20:189-95.
32. Okike N, Bernatz PE, Payne WS, Woolner LB, Leonard PF. Bronchoplastic procedures in the treatment of carcinoid tumors of the tracheobronchial tree. J Thorac Cardiovasc Surg 1978;76:281-91.
33. Cooper DK, Belcher JR. Conservative surgery for bronchial adenomata. Thorax 1976;31:44-8.
34. Rindi G, Bordi C, Rappel S, La Rosa S, Stolte M, Solcia E. Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J Surg 1996;20:168-72.
35. Modlin I, Gilligan CJ, Lawton GP, Tang LH, West AB, Darr U. Gastric carcinoids: the Yale experience. Arch Surg 1995;130:255-6.
36. Bordi C, Yu JY, Baggi MT, et al. Gastric carcinoids and their precursor lesions: a histologic and immunohistochemical study of 23 cases. Cancer 1991;67:663-72.
37. Rindi G, Luinetti O, Cornaggia M, Capella C, Solcia E. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology 1993;104:994-1006.
38. Thomas RM, Baybick JH, Elsayed AM, Sobin LH. Gastric carcinoids: an immunohistochemical and clinicopathologic study of 104 patients. Cancer 1994;73:2053-8.
39. Gough DB, Thompson GB, Crotty TB, et al. Diverse clinical and pathologic features of gastric carcinoid and the relevance of hypergastrinemia. World J Surg 1994;18:473-9.
40. Moses RE, Frank BB, Leavitt M, Miller R. The syndrome of type A chronic atrophic gastritis, pernicious anemia, and multiple gastric carcinoids. J Clin Gastroenterol 1986;8:61-5.
41. Sjoblom SM, Sipponen P, Karonen SL, Jarvinen HJ. Mucosal argyrophil endocrine cells in pernicious anaemia and upper gastrointestinal carcinoid tumours. J Clin Pathol 1989;42:371-7.
42. Solcia E, Fiocca R, Villani L, et al. Morphology and pathogenesis of endocrine hyperplasias, precarcinoid lesions, and carcinoids arising in chronic atrophic gastritis. Scand J Gastroenterol Suppl 1991;180:146-59.
43. Havu N. Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. Digestion 1986;35:Suppl 1: 42-55.
44. Lamberts R, Creutzfeldt W, Struber HG, Brunner G, Solcia E. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology 1993;104:1356-70.
45. Klinkenberg-Knol EC, Festen HP, Jansen JB, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994;121:161-7.
46. Ahlman H, Kolby L, Lundell L, et al. Clinical management of gastric carcinoid tumors. Digestion 1994;55:Suppl 3:77-85.
47. Borch K, Renvall H, Kullman E, Wilander E. Gastric carcinoid associated with the syndrome of hypergastrinemic atrophic gastritis. Am J Surg Pathol 1987;11:435-44.
48. Sjoblom SM, Sipponen P, Jarvinen H. Gastroscopic follow-up of pernicious anaemia patients. Gut 1993;34:28-32.
49. Eckhauser FE, Lloyd RV, Thompson NW, Raper SE, Vinik AI. Antrectomy for multicentric, argyrophil gastric carcinoids: a preliminary report. Surgery 1988;104:1046-53.
50. Hirschowitz BI, Griffith J, Pellegrin D, Cummings OW. Rapid regression of enterochromaffinlike cell gastric carcinoids in pernicious anemia after antrectomy. Gastroenterology 1992;102:1409-18.
51. Solcia E, Capella C, Fiocca R, Rindi G, Rosai J. Gastric argyrophil carcinoidosis in patients with Zollinger-Ellison syndrome due to type I multiple endocrine neoplasia: a newly recognized association. Am J Surg Pathol 1990;14:503-13.
52. Lehy T, Cadiot G, Mignon M, Ruszniewski P, Bonfils S. Influence of multiple endocrine neoplasia type 1 on gastric endocrine cells in patients with the Zollinger-Ellison syndrome. Gut 1992;33:1275-9.
53. Cadiot G, Laurent-Puig P, Thuille B, Lehy T, Mignon M, Olschwang S. Is the multiple endocrine neoplasia type 1 gene a suppressor for fundic argyrophil tumors in the Zollinger-Ellison syndrome? Gastroenterology 1993;105:579-82.
54. Barclay TH, Schapira DV. Malignant tumors of the small intestine. Cancer 1983;51:878-81.
55. Moertel CG, Sauer WG, Dockerty MB, Baggenstoss AH. Life history of the carcinoid tumor of the small intestine. Cancer 1961;14:901-12.
56. Lundqvist M, Wilander E. A study of the histopathogenesis of carcinoid tumors of the small intestine and appendix. Cancer 1987;60:201-6.
57. Moyana TN, Satkunam N. A comparative immunohistochemical study of jejunoileal and appendiceal carcinoids: implications for histogenesis and pathogenesis. Cancer 1992;70:1081-8.
58. Makridis C, Oberg K, Juhlin C, et al. Surgical treatment of mid-gut carcinoid tumors. World J Surg 1990;14:377-85.
59. Burke AP, Thomas RM, Elsayed AM, Sobin LH. Carcinoids of the jejunum and ileum: an immunohistochemical and clinicopathologic study of 167 cases. Cancer 1997;79:1086-93.
60. Akerstrom G, Makridis C, Johansson H. Abdominal surgery in patients with midgut carcinoid tumors. Acta Oncol 1991;30:547-53.
61. Eckhauser FE, Argenta LC, Strodel WE, et al. Mesenteric angiopathy, intestinal gangrene, and midgut carcinoids. Surgery 1981;90:720-8.
62. Moertel CG, Dockerty MB, Judd ES. Carcinoid tumors of the vermiform appendix. Cancer 1968;21:270-8.
63. Lundqvist M, Wilander E. Subepithelial neuroendocrine cells and carcinoid tumours of the human small intestine and appendix: a comparative immunohistochemical study with regard to serotonin, neuron-specific enolase and S-100 protein reactivity. J Pathol 1986;148:141-7.
64. Shaw PA. Carcinoid tumours of the appendix are different. J Pathol 1990;612:189-90.
65. Idem. The topographical and age distributions of neuroendocrine cells in the normal human appendix. J Pathol 1991;164:235-9.
66. Roggo A, Wood WC, Ottinger LW. Carcinoid tumors of the appendix. Ann Surg 1993;217:385-90.
67. Jonsson T, Johannsson JH, Hallgrimsson JG. Carcinoid tumors of the appendix in children younger than 16 years: a retrospective clinical and pathologic study. Acta Chir Scand 1989;155:113-6.
68. Parkes SE, Muir KR, Sheyyab M, et al. Carcinoid tumours of the appendix in children 1957-1986: incidence, treatment and outcome. Br J Surg 1993;80:502-4.
69. Moertel CL, Weiland LH, Telander RL. Carcinoid tumor of the appendix in the first two decades of life. J Pediatr Surg 1990;25:1073-5.
70. Moertel CG, Weiland LH, Nagorney DM, Dockerty MB. Carcinoid tumor of the appendix: treatment and prognosis. N Engl J Med 1987;317: 1699-701.
71. Anderson JR, Wilson BG. Carcinoid tumours of the appendix. Br J Surg 1985;72:545-6.
72. Thirlby R, Kasper CS, Jones RC. Metastatic carcinoid tumor of the appendix: report of a case and review of the literature. Dis Colon Rectum 1984;27:42-6.
73. MacGillivray DC, Heaton RB, Rushin JM, Cruess DF. Distant metastases from a carcinoid tumor of the appendix less than one centimeter in size. Surgery 1992;111:466-71.
74. Bowman GA, Rosenthal D. Carcinoid rumors of the appendix. Am J Surg 1983;146:700-3.
75. Syracuse DC, Perzin KH, Price JB, Wiedel PD, Mesa-Tejada R. Carcinoid tumors of the appendix: mesoappendiceal extension and nodal metastases. Ann Surg 1979;190:58-63.
76. Pearlman D, Srinivasan K. Malignant carcinoid of the appendix: metastasis from small primary tumor which appeared as appendiceal intussusception. N Y State J Med 1971;71:1529-31.
77. Ponka J. Carcinoid tumor of the appendix: report of thirty-five cases. Am J Surg 1973;126:77-83.
78. Rosenberg JM, Welch JP. Carcinoid tumors of the colon: a study of 72 patients. Am J Surg 1985;149:775-9.
79. Berardi RS. Carcinoid tumors of the colon (exclusive of the rectum): review of the literature. Dis Colon Rectum 1972;15:383-91.
80. Ballantyne GH, Savoca PE, Flannery JT, Ahlman MH, Modlin IM. Incidence and mortality of carcinoids of the colon: data from the Connecticut Tumor Registry. Cancer 1992;69:2400-5.
81. Jetmore AB, Ray JE, Gathright JB Jr, McMullen KM, Hicks TC, Timmcke AE. Rectal carcinoids: the most frequent carcinoid tumor. Dis Colon Rectum 1992;35:717-25.
82. Soga J. Carcinoids of the rectum: tumors of the carcinoid family -urgut endocrinomas. Acta Med Biol 1982;29:157-201.
83. Naunheim KS, Zeitels J, Kaplan EL, et al. Rectal carcinoid tumors -treatment and prognosis. Surgery 1983;94:670-6.
84. Sauven P, Ridge JA, Quan SH, Sigurdson ER. Anorectal carcinoid tumors: is aggressive surgery warranted? Ann Surg 1990;211:67-71.
85. Burke M, Shepherd N, Mann CV. Carcinoid tumours of the rectum and anus. Br J Surg 1987;74:358-61.
86. Koura AN, Giacco GG, Curley SA, Skibber JM, Feig BW, Ellis LM. Carcinoid tumors of the rectum: effect of size, histopathology, and surgical treatment on metastasis free survival. Cancer 1997;79:1294-8.
87. Woodard PK, Feldman JM, Paine SS, Baker ME. Midgut carcinoid tumors: CT findings and biochemical profiles. J Comput Assist Tomogr 1995;19:400-5.
88. Sugimoto E, Lorelius LE, Eriksson B, Oberg K. Midgut carcinoid tumours: CT appearance. Acta Radiol 1995;36:367-71.
89. Eriksson B, Arnberg H, Oberg K, et al. A polyclonal antiserum against chromogranin A and B - a new sensitive marker for neuroendocrine tumours. Acta Endocrinol (Copenh) 1990;122:145-55.
90. Janson ET, Holmberg L, Stridsberg M, et al. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 1997;8:685-90.
91. Engstrom PF, Lavin PT, Moertel CG, Folsch E, Douglass HO Jr. Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J Clin Oncol 1984;2:1255-9.
92. Bukowski RM, Johnson KG, Peterson RF, et al. A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors: a Southwest Oncology Group study. Cancer 1987;60:2891-5.
93. Bishopric GA Jr, Ordonez NG. Carcinoembryonic antigen in primary carcinoid tumors of the lung. Cancer 1986;58:1316-20.
94. Federspiel BH, Burke AP, Shekitka KM, Sobin LH. Carcinoembryonic antigen and carcinoids of the gastrointestinal tract. Mod Pathol 1990;3: 586-90.
95. Reichlin S. Somatostatin. N Engl J Med 1983;309:1495-501.
96. Reubi JC, Kvols LK, Waser B, et al. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 1990;50:5969-77.
97. Reisine T, Bell G. Molecular biology of somatostatin receptors. Endocr Rev 1995;16:427-42.
98. Patel YC, Srikant CB. Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5). Endocrinology 1994; 135:2814-7
99. Kubota A, Yamada Y, Kagimoto S, et al. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. J Clin Invest 1994;93:1321-5.
100. Lamberts SWJ, Bakker WH, Reubi JC, Krenning EP. Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med 1990;323:1246-9.
101. Krenning EP, Kwekkeboom DJ, Oei HY, et al. Somatostatin-receptor scintigraphy in gastroenteropancreatic tumors: an overview of European results. Ann N Y Acad Sci 1994;733:416-24.
102. Janson ET, Westlin JE, Eriksson B, Ahlstrom H, Nilsson S, Oberg K. [111In-DTPA-D-Phe1]octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment. Eur J Endocrinol 1994;131:577-81.
103. Kvols LK, Moertel CG, O'Connell MJ, Schutt AJ, Rubin J, Hahn RG. Treatment of the malignant carcinoid syndrome: evaluation of a longacting somatostatin analogue. N Engl J Med 1986;315:663-6.
104. Di Bartolomeo M, Bajetta E, Buzzoni R, et al. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors: a study by the Italian Trials in Medical Oncology Group. Cancer 1996;77:402-8.
105. Ruszniewski P, Ducreux M, Chayvialle JA, et al. Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut 1996;39:279-83.
106. Lundin L, Norheim I, Landelius J, Oberg K, Theodorsson-Norheim E. Carcinoid heart disease: relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities. Circulation 1988;77:264-9.
107. Robiolio PA, Rigolin VH, Wilson JS, et al. Carcinoid heart disease: correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation 1995;92:790-5.
108. Pellikka PA, Tajik AJ, Khandheria BK, et al. Carcinoid heart disease: clinical and echocardiographic spectrum in 74 patients. Circulation 1993; 87:1188-96.
109. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581-8. [Erratum, N Engl J Med 1997;337:1783.]
110. Khan MA, Herzog CA, St Peter JV, et al. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. N Engl J Med 1998;339: 713-8.
111. Jick H, Vasilakis C, Weinrauch LA, Meier CR, Jick SS, Derby LE. A population-based study of appetite suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med 1998;339:719-24.
112. Weissman NJ, Tighe JF Jr, Gottdiener JS, Gwynne JT. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. N Engl J Med 1998;339:725-32.
113. Robiolio PA, Rigolin VH, Harrison JK, et al. Predictors of outcome of tricuspid valve replacement in carcinoid heart disease. Am J Cardiol 1995;75:485-8.
114. Connolly HM, Nishimura RA, Smith HC, Pellikka PA, Mullany CJ, Kvols LK. Outcome of cardiac surgery for carcinoid heart disease. J Am Coll Cardiol 1995;25:410-6.
115. Que FG, Nagorney DM, Batts KP, Linz LJ, Kvols LK. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 1995;169: 36-43.
116. McEntee GP, Nagorney DM, Kvols LK, Moertel CG, Grant CS. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 1990;108: 1091-6.
117. Dousset B, Saint-Marc O, Pitre J, Soubrane O, Houssin D, Chapuis Y. Metastatic neuroendocrine tumors: medical treatment, surgical resection, or liver transplantation. World J Surg 1996;20:908-15.
118. Mitty HA, Warner RR, Newman LH, Train JS, Parnes IH. Control of carcinoid syndrome with hepatic artery embolization. Radiology 1985; 155:623-6.
119. Maton PN, Camilleri M, Griffin G, Allison DJ, Hodgson HJ, Chadwick VS. Role of hepatic arterial embolisation in the carcinoid syndrome. BMJ 1983;287:932-5.
120. Ruszniewski P, Rougier P, Roche A, et al. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors: a prospective phase II study in 24 patients. Cancer 1993;71:2624-30.
121. Nobin A, Mansson B, Lunderquist A. Evaluation of temporary liver dearterialization and embolization in patients with metastatic circinoid tumour. Acta Oncol 1989;28:419-24.
122. Clouse ME, Perry L, Stuart K, Stokes KR. Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Digestion 1994;55:Suppl 3:92-7.
123. Carrasco CH, Charnsangavej C, Ajani J, Samaan NA, Richli W, Wallace S. The carcinoid syndrome: palliation by hepatic artery embolization. AJR Am J Roentgenol 1986;147:149-54.
124. Moertel CG, Johnson CM, McKusick MA, et al. The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med 1994;120:302-9.
125. Bechstein WO, Neuhaus P. Liver transplantation for hepatic metastases of neuroendocrine tumors. Ann N Y Acad Sci 1994;733:507-14.
126. Lang H, Oldhafer KJ, Weimann A, et al. Liver transplantation for metastatic neuroendocrine tumors. Ann Surg 1997;225:347-54.
127. Le Treut YP, Delpero JR, Dousset B, et al. Results of liver transplantation in the treatment of metastatic neuroendocrine tumors: a 31-case French multicentric report. Ann Surg 1997;225:355-64.
128. Öberg K, Funa K, Alm G. Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. N Engl J Med 1983;309:129-33.
129. Oberg K, Eriksson B. The role of interferons in the management of carcinoid tumors. Acta Oncol 1991;30:519-22.
130. Janson ET, Oberg K. Long-term management of the carcinoid syndrome: treatment with octreotide alone and in combination with alpha interferon. Acta Oncol 1993;32:225-9.
131. Moertel CG, Hanley JA. Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin Trials 1979;2:327-34.
132. Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin: evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991;68:227-32.
133. Schupak KD, Wallner KE. The role of radiation therapy in the treatment of locally unresectable or metastatic carcinoid tumors. Int J Radiat Oncol Biol Phys 1991;20:489-95.
134. McCarthy KE, Woltering EA, Espenan GD, Cronin M, Maloney TJ, Anthony LB. In situ radiotherapy with 111In-pentetreotide: initial observations and future directions. Cancer J Sci Am 1998;4:94-102.
135. Otte A, Mueller-Brand J, Dellas S, Nitzsche EU, Herrmann R, Maecke HR. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 1998;351:417-8.